MetaCap

Lexeo Therapeutics Inc. (LXEO)

NASDAQ: LXEOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.96+0.01 (+0.34%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LXEO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$245.05M
EPS (TTM)
-$1.13
52-week range
2.55 – 10.99
Day range
2.89 – 3.25
Volume / Avg
1.80M / 1.98M
Beta
—

52-week range

$2.55$10.99

LXEO stock today

Lexeo Therapeutics (LXEO) closed at $2.96 on Nov 20, up 0.34% (+$0.01), versus the S&P 500's 3.70% decline. At this level, LXEO sits near the bottom of its 52-week range of $2.55 to $10.99: 73.1% below the high, set on Dec 23, 2025 and 16.1% above the low. LXEO is down 70.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.3%.

Lexeo Therapeutics has posted a net loss over the last twelve months (EPS of -$1.13), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lexeo Therapeutics

Company profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. R. Nolan Townsend M.B.A.
Headquarters
New York, NY
Employees
68
IPO year
2023

Financial highlights

Full financials

Lexeo Therapeutics reported a net loss of $100.0 million, compared with a loss of $98.3 million a year earlier. Diluted earnings per share came in at -$1.86.

Lexeo Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue———$654.00K
Growth————
Net income$-100.00M$-98.33M$-66.39M$-59.28M
EPS (diluted)$-1.86$-3.09$-12.40$-36.36

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$25.11+748.31%

  • Strong buy 2
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $42.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.43 vs $-0.33
Surprise
-30.30%

LXEO news

All LXEO news

Lexeo Therapeutics peers

Health Care sector
LXEO peer companies
CompanyPrice% ChgMarket capCompare
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs LXEO
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs LXEO
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs LXEO
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs LXEO
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs LXEO
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs LXEO
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs LXEO
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs LXEO

Indexes, lists and sector

Lexeo Therapeutics stock FAQ

What is Lexeo Therapeutics's stock price today?

LXEO last traded at $2.96 as of Nov 20, 4:00 PM EST, up 0.34% on the day. Prices are delayed at least 15 minutes.

Who is Lexeo Therapeutics's CEO?

Mr. R. Nolan Townsend M.B.A. is the chief executive officer of Lexeo Therapeutics Inc., which has about 68 employees.

What is the LXEO 52-week high?

The 52-week high for LXEO is $10.99 and the 52-week low is $2.55. The stock is currently 73.1% below its high.

Compare LXEO